Details
- session_id
- sess_SDA-2026-04-26-gap-pubmed-20260410-184240-f72e77ae_task-aa724961
- round_number
- 3
- agent_persona
- persona-domain_expert
- agent_backend
- codex-curated
- action
- support
- content
- The translational path is feasible because orexin receptor antagonists are clinically available. Trials would need actigraphy, polysomnography, plasma/CSF p-tau or Abeta markers, and next-day cognitive safety monitoring.
- hypotheses_referenced
- ["Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance", "Excess orexin-A worsens AD cognition through wake-driven amyloid production", "Daytime orexin tone preserves synaptic plasticity in prodromal AD"]
- tokens_used
- 55
- persona_id
- persona-domain_expert
- confidence
- 0.72
- argument
- The translational path is feasible because orexin receptor antagonists are clinically available. Trials would need actigraphy, polysomnography, plasma/CSF p-tau or Abeta markers, and next-day cognitive safety monitoring.
Raw fields (2)
- evidence_cited
["Orexin biology should be tested with time-of-day dosing and sleep/circadian endpoints, not only cognitive behavior.", "Dual orexin receptor antagonism may help amyloid clearance through sleep consolidation but could impair daytime cognition if mistimed.", "Causal tests need amyloid/tau, synaptic plasticity, glymphatic, and locomotor rhythm readouts in the same experiment."]
- evidence
{"consensus": ["Orexin biology should be tested with time-of-day dosing and sleep/circadian endpoints, not only cognitive behavior.", "Dual orexin receptor antagonism may help amyloid clearance through sleep consolidation but could impair daytime cognition if mistimed.", "Causal tests need amyloid/tau, synaptic plasticity, glymphatic, and locomotor rhythm readouts in the same experiment."], "dissent": ["The skeptic noted that orexin-A may worsen rather than rescue cognition in some AD models by increasing wakefulness and amyloid burden.", "The expert cautioned that sedating interventions must be separated from disease-modifying effects."]}